Source Code

SourceCode Communications has signed a trio of new clients. The agency will develop and execute a global communications strategy for 37.5 Technology, a Colorado-based company that produces a fabric that aims to increase athlete performance. For Grid Connect, which carries and distributes networking products from manufacturers throughout the world, SourceCode will focus on building consumer awareness for the company’s  ConnectSense brand while positioning company executives as thought leaders in the IoT space.  Their work for Puls, which offers on-demand technician services, will include corporate storytelling, executive positioning and creative campaign management “These new client relationships further expand the breadth of SourceCode’s portfolio into one of our core vertical sectors, consumer tech,” said SourceCode Communications Managing Partner, Becky Honeyman.

Bitfinex

5W Public Relations has been named PR agency of record for cryptocurrency exchange Bitfinex. The company says it is the world’s largest exchange by volume for trading Bitcoin against the US Dollar, and experienced record trading in the third quarter of 2017. It also facilitates the trading of seven other altcoins including Ethereum and Monero. Bitfinex CSO Phil Potter noted that because of the company’s focus on building the cryptocurrency exchange, it has lagged as regards communications with stakeholders. “We’ve brought on one of the premier PR firms in the country to help us with these challenges and demonstrate for the industry and larger business community the importance of our company to the space,” he said. 

Ampio

LaVoieHealthScience has signed on to provide services in investor and public relations for Ampio Pharmaceuticals, Inc. LaVoie will support Ampio by designing and executing a strategic communications plan to reach audiences including media, healthcare professionals and the investment community. Ampio’s lead product candidate, Ampion™, a biologic that treats the signs and symptoms of severe osteoarthritis of the knee, is currently in a Phase 3 clinical trial. “As we continue to move forward with Ampion, we believe this is the right time to engage with a strategic communications firm and LHS is the right choice given their deep industry experience,” said Ampio chairman and CEO Michael Macaluso. “We look forward to working with the LaVoieHealthScience team."